AR and neoplasm: Genomic studies have identified several key genetic aberrations, such as alterations in the androgen receptor (AR) signaling pathway, TMPRSS2-ERG fusion, and mutations in tumor suppressor genes, which contribute to the development and aggressiveness of prostate cancer2.